Diagnostic biomarkers continue to address challenges such as early and accurate diagnosis of most of the fatal diseases. Increasing advancements with extended applications of diagnostic biomarkers are only going to increase its significance in the field of diagnostics.
Portland, OR -- (SBWIRE) -- 01/10/2018 -- Biomarkers Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $30.6 billion by 2020, registering a CAGR of 16% during the period 2013 to 2020. Disease diagnostic remains the key application segment that is expected to reach $6.1 billion in 2020. However application of diagnostic biomarkers in forensics and molecular diagnostics is catching up quite significantly with latter expected to experience a growth rate of 17.6% during 2013 and 2020.
Diagnostic biomarker technology is expected to change the scenario of drug development and medical practice, as technologies are metamorphosing from traditional pathophysiology/epidemiology approach to biomarker studies such as genomics and proteomic add the analysts.
Get the PDF Sample Copy of this report
Diagnostic biomarkers though are a great tool in molecular diagnostics, is facing challenges with respect to ethical and regulatory issues as these are relat to a genomic pattern of an individual which needs to be extremely confidential.
Asia Pacific is expected to have the highest CAGR at 20.3% from 2013 to 2020.
Key Benefits For Stakeholders:
-The report offers an assessment and ranking of the factors that favor the biomarkers market growth and those factors which act as a hindrance for the growth of the market.
-Forecast period for estimating market size is from 2013 to 2020. Two historic years include 2011 and 2012.
-The report identifies top investment pockets and offers an analysis of top winning strategies for diagnostic biomarker industry.
-The report analyses the various strategies adopted by some of the key companies in the industry.
-The report tracks and analyses key innovations and patents for biomarkers in the last five years.
Click Here, To Make a Purchase Request of this Report
Companies profiled and analyzed in this report include:
-Roche Diagnostic Limited (Switzerland)
-Siemens Healthcare (Germany)
-Abbott Laboratories Inc. (U.S.)
-Thermo Fisher Scientific, Inc. (U.S.)
-Agilent Technologies Inc. (U.S.)
-Bio-Rad Laboratories Inc. (U.S.)
-Aushon BioSystem Inc. (U.S.)
-Epistem Ltd. (U.K.)
G.E. Healthcare Inc. (U.K)